{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"103"}],"units":"Participants"}],"description":"The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized and treated Part 1 participants only","reportingStatus":"POSTED","timeFrame":"Up to 28 months","title":"Part 1: Number of Deaths During the On-Treatment Period","type":"SECONDARY","unitOfMeasure":"Participants"}